×

img Acces sibility Controls

Technologies Banner

Life Sciences & Biotechnology

CDRI 1703F003 for PCOS Management

Implementing Organization

Central Research Institute (CRI)
CSIR-Central Drug Research Institute (CSIR-CDRI), Uttar Pradesh

About

As a part of our nutraceutical/dietary supplement development program, we found that 50 and 150 mg/kg body weight doses of the bioactive compound N017-0036 and its enriched fraction 1703-F003 respectively improved the ovarian health by increasing the preovulatory follicles and ovulation potential (corpus luteum) at the same time decreasing the cystic follicles. The pure compound N017-0036 alone improves the ovulation independently in the PCOS animal model. The proposed nutraceutical product (1703-F003) development has enormous clinical application and market potential.
Funding Organization
Funding Organization

Quick Information
Area of Research
Chemical Sciences
Focus Area
Management of PCOS
Status
completed
Output in Numbers
Research Paper
00
Technologies (If Any)
00
PhD Produced
N/A
Startup (If Any)
00
Patents
Filed :00
Grant :00
arrowtop